Literature DB >> 24841261

Convulsive liability of cefepime and meropenem in normal and corneal kindled mice.

Akihiro Tanaka1, Kenshi Takechi2, Shinichi Watanabe2, Mamoru Tanaka2, Katsuya Suemaru3, Hiroaki Araki2.   

Abstract

We have reported significantly higher convulsion prevalence in patients treated with cefepime than in those treated with meropenem. Additionally, cefepime-associated convulsions were found only in patients with brain disorders, not renal failure. Here, we compared the convulsive liability of cefepime and meropenem administered intravenously in normal and corneal kindled mice with low seizure thresholds. We used the proconvulsive test in normal mice following pentylenetetrazol (PTZ) injection and electroconvulsive shock at low-stimulus currents and in corneal kindled mice. We also measured electroencephalogram (EEG) activity 1 min after antibiotic injections. Intravenous injection of cefepime and meropenem at 250 or 500 mg/kg of body weight had no effect on PTZ-induced convulsions in normal mice. However, in convulsions induced by electroconvulsive shock at low-stimulus currents, mean seizure stage following cefepime administration at 500 mg/kg was significantly higher than that following saline injection. Additionally, EEG spikes were recorded for mice that were given cefepime (500 mg/kg). In corneal kindled mice following cefepime injection, mean seizure stage was significantly higher than that following meropenem injection. The convulsive liability of cefepime is significantly higher than that of meropenem in normal and corneal kindled mice. In patients with low seizure thresholds, convulsive liability of cefepime may be assumed.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24841261      PMCID: PMC4136054          DOI: 10.1128/AAC.02862-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  Modification of seizure activity by electrical stimulation. II. Motor seizure.

Authors:  R J Racine
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1972-03

2.  Regulatory role of the dopamine and norepinephrine transporters in pentylenetetrazol-kindled mice: association with effect of antidepressants.

Authors:  Kenshi Takechi; Katsuya Suemaru; Hiromu Kawasaki; Hiroaki Araki
Journal:  Eur J Pharmacol       Date:  2011-10-25       Impact factor: 4.432

3.  Comparative anticonvulsant efficacy in the corneal kindled mouse model of partial epilepsy: Correlation with other seizure and epilepsy models.

Authors:  Nicole M Rowley; H Steve White
Journal:  Epilepsy Res       Date:  2010-10-14       Impact factor: 3.045

Review 4.  Cefepime neurotoxicity: case report, pharmacokinetic considerations, and literature review.

Authors:  Sum Lam; Irving H Gomolin
Journal:  Pharmacotherapy       Date:  2006-08       Impact factor: 4.705

5.  Assessment of seizure susceptibility in pilocarpine epileptic and nonepileptic Wistar rats and of seizure reinduction with pentylenetetrazole and electroshock models.

Authors:  Miriam Marcela Blanco; Jair Guilherme dos Santos; Patrícia Perez-Mendes; Silvia R B Kohek; Clarissa Fantin Cavarsan; Michele Hummel; Cristovão Albuquerque; Luiz E Mello
Journal:  Epilepsia       Date:  2008-11-19       Impact factor: 5.864

6.  Evidence for the involvement of GABA(A) receptor blockade in convulsions induced by cephalosporins.

Authors:  Masahiro Sugimoto; Ichiro Uchida; Takashi Mashimo; Shunji Yamazaki; Kazuo Hatano; Fumiaki Ikeda; Yoshitaka Mochizuki; Takao Terai; Nobuya Matsuoka
Journal:  Neuropharmacology       Date:  2003-09       Impact factor: 5.250

Review 7.  The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions.

Authors:  Michael A Rogawski; Wolfgang Löscher
Journal:  Nat Med       Date:  2004-07       Impact factor: 53.440

Review 8.  Efficacy and safety of cefepime: a systematic review and meta-analysis.

Authors:  Dafna Yahav; Mical Paul; Abigail Fraser; Nadav Sarid; Leonard Leibovici
Journal:  Lancet Infect Dis       Date:  2007-05       Impact factor: 25.071

9.  Prospective randomized comparison of cefepime and cefotaxime for treatment of bacterial meningitis in infants and children.

Authors:  X Sáez-Llorens; E Castaño; R García; C Báez; M Pérez; F Tejeira; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1995-04       Impact factor: 5.191

10.  Cefepime neurotoxicity in patients with renal insufficiency.

Authors:  Seon-Yu Kim; In-Sik Lee; Seung Lee Park; Jongmin Lee
Journal:  Ann Rehabil Med       Date:  2012-02-29
View more
  2 in total

1.  Paradoxical Anticonvulsant Effect of Cefepime in the Pentylenetetrazole Model of Seizures in Rats.

Authors:  Dmitry V Amakhin; Ilya V Smolensky; Elena B Soboleva; Aleksey V Zaitsev
Journal:  Pharmaceuticals (Basel)       Date:  2020-04-26

Review 2.  Setting the Beta-Lactam Therapeutic Range for Critically Ill Patients: Is There a Floor or Even a Ceiling?

Authors:  Erin F Barreto; Andrew J Webb; Gwendolyn M Pais; Andrew D Rule; Paul J Jannetto; Marc H Scheetz
Journal:  Crit Care Explor       Date:  2021-06-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.